Compare PGY & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | SGP |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | 518 | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | PGY | SGP |
|---|---|---|
| Price | $13.63 | $23.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $34.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 3.7M | 49.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.39 | N/A |
| P/E Ratio | $13.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $20.15 |
| 52 Week High | $44.99 | $30.56 |
| Indicator | PGY | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 44.29 |
| Support Level | $10.78 | $20.95 |
| Resistance Level | $15.57 | $26.29 |
| Average True Range (ATR) | 0.85 | 1.47 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 18.60 | 38.44 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.